Childhood brainstem astrocytoma

Summary

Childhood brainstem astrocytoma (MONDO:0003870) is a disease. A subtype of childhood astrocytic tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood brainstem astrocytoma
Mondo ID	MONDO:0003870
DOID	DOID:6386
NCIT	C6216
UMLS	C1332950
MedGen	234123
GARD	0023707
Is cancer (heuristic)	no

Also known as: brain stem astrocytic neoplasm of childhood · childhood brain stem astrocytic neoplasm · childhood brain stem astrocytoma · childhood brainstem astrocytoma · paediatric brain stem astrocytic neoplasm · pediatric brain stem astrocytic neoplasm

Disease family

This is a subtype of childhood astrocytic tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › childhood neoplasm › childhood astrocytic tumor › childhood brainstem astrocytoma

Related subtypes (3): childhood cerebellar astrocytic neoplasm, childhood pilocytic astrocytoma, childhood cerebral astrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.